New Study using Large-scale Gene Expression Microarray Analysis
News Jun 15, 2012
DNA methylation is one of the main epigenetic mechanisms and hypermethylation of CpG islands at tumor suppressor genes switches off these genes. To find novel DNA methylation markers in hepatocellular carcinoma (HCC), we performed pharmacological unmasking (treatment with 5-aza-2'-deoxycytidine or trichostatin A) followed by microarray analysis in HCC cell lines. Of the 239 promoter CpG island loci hypermethylated in HCC cell lines (as revealed by methylation-specific PCR), 221 loci were found to be hypermethylated in HCC or nonneoplastic liver tissues. Thirty-three loci showed a 20% higher methylation frequency in tumors than in adjacent nonneoplastic tissues. Correlation of individual cancer-related methylation markers with clinicopathological features of HCC patients (n = 95) revealed that the number of hypermethylated genes in HCC tumors was higher in older than in younger patients. Univariate and multivariate survival analysis revealed that the HIST1H2AE methylation status is closely correlated with the patient's overall survival (P = 0.022 and P = 0.010, respectively). In conclusion, we identified 221 novel DNA methylation markers for HCC. One promising prognostic marker, HIST1H2AE, should be further validated in the prognostication of HCC patients.
This article is published online in the Journal of Korean Medical Science and is free to access.
Holding Infants – or not – Can Leave Traces on Their GenesNews
Children who have been more distressed as infants and have received less physical contact have a molecular profile that is underdeveloped for their age – pointing to the possibility that they are lagging biologically.READ MORE
Revealing the Role of the Centromere in Down SyndromeNews
The centromere plays a crucial role in the everyday cell division that keeps us healthy but is also potentially involved in birth defects, cancers and other diseases that arise from cell division problems.READ MORE
Cambridge Epigenetix Appoints Professor Mark Dawson as Scientific AdvisorNews
Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, announced the appointment of leading epigenetics-based therapeutics specialist, Professor Mark Dawson to its Scientific Advisory Board (SAB).READ MORE